These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 22944158)

  • 21. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between inflammation and arterial stiffness in patients with essential hypertension.
    Kampus P; Muda P; Kals J; Ristimäe T; Fischer K; Teesalu R; Zilmer M
    Int J Cardiol; 2006 Sep; 112(1):46-51. PubMed ID: 16297996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk.
    Sathiyapriya V; Selvaraj N; Nandeesha H; Bobby Z; Aparna A; Pavithran P
    Clin Exp Hypertens; 2008 Jul; 30(5):367-74. PubMed ID: 18633759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
    Yee LL; Wright EA
    Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
    Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitavastatin improves serum resistin levels in patients with hypercholesterolemia.
    Ohbayashi H
    J Atheroscler Thromb; 2008 Apr; 15(2):87-93. PubMed ID: 18385536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial.
    Berthold HK; Schulte DM; Lapointe JF; Lemieux P; Krone W; Gouni-Berthold I
    J Dairy Sci; 2011 Feb; 94(2):589-601. PubMed ID: 21257028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
    Hu M; Lee MH; Mak VW; Tomlinson B
    Am J Cardiol; 2010 Dec; 106(11):1588-93. PubMed ID: 21094359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.
    Fukutomi T; Takeda Y; Suzuki S; Ito T; Joh T; Itoh M
    Int J Cardiol; 2010 Jun; 141(3):320-2. PubMed ID: 19138801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Different effects of inflammation and lipid levels on coronary lesions after PCI].
    Xu HY; Qiao SB; Li JJ; Yang YJ; Zhang JF; Xu B; Xie GQ; Dong QT
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2249-52. PubMed ID: 20095335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.